drugset

drugset / Trial / NCT00072722

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00072722 ↗

Phase 2 Completed 36 enrolled Celgene Corporation

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase II randomized open-label, two-arm study of safety and efficacy of CC-4047 in subjects with metastatic hormone refractory prostate cancer (HRPC)

Timeline

Start: 2003-09
Primary completion: —
Completion: 2005-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pomalidomide	Other / unclassified	—	—

Indications